Derivatives of the COX-2 inhibitor celecoxib can trigger cancer cell suicide, or apoptosis, but not necessarily through the recognized means of blocking COX-2 enzyme activity, a new study concludes. By separating COX-2 activity from apoptosis, researchers have a starting point for designing new classes of anticancer drugs, write Xueqin Song, Ching-Shih Chen, Ph.D., Ohio State University, and their coworkers in the April 17 issue of the Journal of the National Cancer Institute
Celecoxib, an anti-inflammation pill for arthritis, is being studied for its potential in preventing and treating certain cancers. In a large percentage of tumors, the COX-2 enzyme is elevated, say Ernest T. Hawk, M.D., M.P.H., of the National Cancer Institute, and his coworkers in an accompanying editorial. They point out that past studies have shown that decreasing levels of COX-2 can suppress the growth of tumors. However, it has been unclear whether celecoxibs anticancer effects depend on COX-2 inhibition alone.
To find out, Chen and his coworkers created prostate cancer cells lacking the COX-2 enzyme. In contrast to the effects of COX-2 inhibitors such as celecoxib, which induce cell death, cells that lacked COX-2 remained alive. Exposure of these cells lacking COX-2 to various COX-2 inhibitors did lead to cell death. Whats more, derivatives of celecoxib that did not block COX-2 activity also caused cell death.
The authors note that these events were associated not with levels of COX-2 but with decreased phosphorylation of Akt and ERK2 proteins. This mode of action differs from that of conventional anticancer drugs, they point out.
In the accompanying editorial, Hawk and his colleagues note that celecoxib is being tested for the treatment and prevention of colon cancer and that newer generations of COX-2 inhibitors could prove to be safer and more effective.
However, they point out that the current findings are based on concentrations of cPage: 1 2 Related biology news :1
Contact: Linda Wang
Journal of the National Cancer Institute
. Anticancer drug zebularine specifically targets tumor cells2
. The Bodys Anticancer Weaponry Backfires In Old Age3
. Enzymes "Magic" May Hold Key to Anticancer and Antimicrobial Drugs4
. Hidden diversity: DNA barcoding reveals a common butterfly is actually 10 different species5
. Brown research reveals key insight into memory-making6
. Study reveals why eyes in some paintings seem to follow viewers7
. New dye directly reveals activated proteins in living cells8
. Study reveals first genetic step necessary for prostate cancer growth9
. Study of flu patients reveals virus outsmarting key drug10
. Study in Science reveals recreational fishing takes big bite of ocean catch11
. Plumbing trees plumbing reveals their engineering skill